Cue Biopharma Prices $20M Public Offering to Boost Therapeutic Development

Cue Biopharma, a clinical-stage biopharmaceutical company focused on the development of therapeutic biologics that engage disease-specific T cells, announced a public offering of around $20 million. The offering includes common stock and warrants, with some pre-funded warrants also available to certain investors. This financial move is pivotal for the company as it aims to progress its therapeutic pipeline, especially in cancer and autoimmune diseases. Furthermore, Cue Biopharma has entered a promising strategic collaboration and license agreement with Boehringer Ingelheim, specifically targeting the development of CUE-501, a therapy aimed at B cell depletion for autoimmune diseases. With the proceeds from the public offering and the new partnership, Cue Biopharma is poised for significant advancements in its therapeutic offerings.